Unique ID issued by UMIN | UMIN000020200 |
---|---|
Receipt number | R000023110 |
Scientific Title | The efficacy of sodium-dependent glucose co-transporter 2(SGLT2) inhibitors for pericardial fat in the type 2 diabetes patients |
Date of disclosure of the study information | 2015/12/15 |
Last modified on | 2015/12/22 09:36:13 |
The efficacy of sodium-dependent glucose co-transporter 2(SGLT2) inhibitors for pericardial fat in the type 2 diabetes patients
The efficacy of SGLT2 inhibitors for pericardial fat in the type 2 diabetes patients
The efficacy of sodium-dependent glucose co-transporter 2(SGLT2) inhibitors for pericardial fat in the type 2 diabetes patients
The efficacy of SGLT2 inhibitors for pericardial fat in the type 2 diabetes patients
Japan |
Type 2 diabetes patients with pericardial fat is more than 125 ml
Cardiology |
Others
NO
Patients with 125ml or more pericardial fat have been reported to have a high risk for ischemic heart disease. Sodium dependent glucose co-transporter 2(SGLT2) inhibitor Dapagliflozin has been reported as being approved in Europe and the United States and Japan, fewer side effects, weight loss, and abdominal visceral fat is reduced. This study is to investigate the efficacy of SGLT2 inhibitors for pericardial fat in the type 2 diabetes patients.
Efficacy
Exploratory
Not applicable
We administered the dapagliflozin to the patient, and observe the changes in the CT value of the amount and pericardial fat.
We will observe changes in the subjective symptoms, objective findings, and clinical examination (blood biochemistry, electrocardiogram, ABI). In addition, we will evaluate the safety of such adverse events.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1) Patients who obtained the start or switching of consent the dapagliflozin of SGLT2 inhibitors.
2) Patients with pericardial fat is more than 125ml in coronary CT angiography.
3) Patient age of 20 years or older at the time of obtaining informed consent.
4) Patients who themselves can voluntarily provide consent to participate in this study, and can also follow the study protocol.
1)Patients with decreased renal function.
2)Patient corresponding to the contraindications and careful administration of SGLT2 inhibitors.
3)Patients research investigator has determined to be inappropriate as a patient.
30
1st name | |
Middle name | |
Last name | Takehito Shizuka |
National Hospital Organization Takasaki General Medical Center
Division of Cardiology
36 Takamatsu-cho, Takasaki-city, Gunma
027-322-5901
tshizuka8@gmail.com
1st name | |
Middle name | |
Last name | Takehito Shizuka |
National Hospital Organization Takasaki General Medical Center
Division of Cardiology
36 Takamatsu-cho, Takasaki-city, Gunma
027-322-5901
tshizuka8@gmail.com
National Hospital Organization Takasaki General Medical Center
None
Self funding
NO
2015 | Year | 12 | Month | 15 | Day |
Unpublished
Preinitiation
2015 | Year | 11 | Month | 27 | Day |
2015 | Year | 12 | Month | 21 | Day |
Study design:Prospective Cohort Study
Subject recruitment method:Patients were consistent with a visit to selection criteria to our facility in December 2015 to October 2016.
2015 | Year | 12 | Month | 15 | Day |
2015 | Year | 12 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023110